Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TCR2 Therapeutics Inc. - Common Stock
(NQ:
TCRR
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 31, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TCR2 Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
↗
May 11, 2023
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
Recap: TCR2 Therapeutics Q1 Earnings
↗
May 11, 2023
Via
Benzinga
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
What To Know About Jefferies's Downgrade of TCR2 Therapeutics
↗
March 09, 2023
Via
Benzinga
4 Analysts Have This to Say About TCR2 Therapeutics
↗
March 09, 2023
Via
Benzinga
Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company
↗
March 06, 2023
Via
Benzinga
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
↗
May 08, 2023
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in...
Via
Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
April 26, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –
March 30, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
↗
March 24, 2023
Via
Benzinga
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
↗
March 09, 2023
Via
Benzinga
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
March 08, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
↗
March 08, 2023
Via
Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
↗
March 07, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
↗
March 07, 2023
Via
Benzinga
Why Is TCR2 Therapeutics Stock Trading Higher Today?
↗
March 06, 2023
TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to...
Via
Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
March 06, 2023
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
March 06, 2023
Via
Benzinga
TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company
March 06, 2023
TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of
Via
Spotlight Growth
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
↗
March 06, 2023
A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.
Via
InvestorPlace
TCRR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of TCR² Therapeutics Inc. Is Fair to Shareholders
March 06, 2023
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
March 06, 2023
Via
Benzinga
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...
Via
Newsfile
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
February 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
↗
January 06, 2023
Gene-editing stocks have not been immune when it comes to job losses and workforce reductions. Here are a few of the latest.
Via
InvestorPlace
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
January 06, 2023
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
